Free tool
FAERS Monitor: Ic-Green
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 011525 or its brand name (Ic-Green, Indocyanine Green). Reports on generic versions are filed under their own applications.
Reports
121
Serious
105
87% of reports
Hospitalization
25
Death reported
1
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- palpitations10
- urticaria10
- off label use9
- visual acuity reduced9
- drug ineffective8
- dyspnoea8
- haemangioma congenital8
- low birth weight baby8
- patent ductus arteriosus8
- rash8
- disease progression7
- hypotension7
- liver function test increased7
- abdominal pain6
- dizziness6
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2008 | 1 |
| 2009 | 3 |
| 2010 | 2 |
| 2011 | 2 |
| 2012 | 6 |
| 2014 | 5 |
| 2015 | 2 |
| 2016 | 8 |
| 2017 | 8 |
| 2018 | 17 |
| 2019 | 7 |
| 2020 | 5 |
| 2021 | 3 |
| 2022 | 13 |
| 2023 | 11 |
| 2024 | 6 |
| 2025 | 11 |
| 2026 | 11 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,038 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| haemangioma congenitalSignal | 8 | 2974.4 | 1513.3 | 20,548 |
| patent ductus arteriosusSignal | 8 | 351.0 | 179.5 | 2,448 |
| low birth weight babySignal | 8 | 175.2 | 89.6 | 1,216 |
| liver function test increasedSignal | 7 | 56.7 | 27.6 | 330 |
| visual acuity reducedSignal | 9 | 47.1 | 25.1 | 362 |
| palpitationsSignal | 10 | 14.8 | 8.2 | 116 |
| urticariaSignal | 10 | 10.4 | 5.7 | 76 |
| disease progressionSignal | 7 | 10.3 | 5.0 | 50 |
| hypotensionSignal | 7 | 6.1 | 3.0 | 25 |
| abdominal painSignal | 6 | 4.5 | 2.1 | 13 |
| rashSignal | 8 | 3.2 | 1.6 | 10 |
| dyspnoeaSignal | 8 | 2.5 | 1.3 | 6 |
| dizziness | 6 | 2.1 | 1.0 | 2 |
| off label use | 9 | 1.8 | 1.0 | 2 |
| drug ineffective | 8 | 1.1 | 0.5 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.